Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06301048
Other study ID # BFHHZS20230203
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 7, 2023
Est. completion date December 7, 2023

Study information

Verified date January 2024
Source Beijing Friendship Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a retrospective study, including 79 patients with duodenal papillary adenoma, who treated with Endoscopic Papillectomy (EP) at Beijing friendship hospital. The cohort included patients who underwent EP with or without Pancreatic Duct (PD) and Common Bile Duct (CBD) stent placement. The investigators assessed the outcomes of EP and the impact of stent placement on complications and recurrence rates.


Description:

Duodenal papillary adenoma, a potentially malignant benign tumor is primarily treated with endoscopic papillectomy. Despite its efficacy, endoscopic papillectomy has a high complication rate. This study investigates whether pancreatic duct and common bile duct stent placement can mitigate these complications. In a retrospective analysis, 79 patients with duodenal papillary adenoma, treated with endoscopic papillectomy at our center, were studied. The cohort included patients who underwent endoscopic papillectomy with no stents placement, common bile duct stent placement alone, pancreatic duct stent placement alone, or stents placement in both ducts. Complete resection rates did not significantly differ between patients with or without stent placement. Early complication rates were similar across groups. However, significant reduction in common bile duct stenosis was observed in the stenting group. Furthermore, stent placement correlated with lower adenoma recurrence rates during follow-up. Thus, Pancreatic duct and common bile duct stent placement in endoscopic papillectomy may decrease late complications, particularly common bile duct stenosis, and reduce the recurrence of duodenal papillary adenoma.


Recruitment information / eligibility

Status Completed
Enrollment 79
Est. completion date December 7, 2023
Est. primary completion date December 7, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years. - Identification of duodenal papillary lesions via gastroscopy or duodenoscopy. - Intraductal involvement <20mm. - Absence of preoperative peripheral lymph node metastasis and pancreatic/biliary duct stenosis (verified by CT, MRI, or other imaging). - Postoperative biopsy confirming adenoma. Exclusion Criteria: - Diagnosis of familial adenomatous polyposis or multiple hamartoma syndrome. - Patients undergoing pancreaticoduodenectomy within a month post-EP for residual lesions.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Stent Placement in Pancreatic and Bile Ducts
Post-resection, endoscopic retrograde cholangiopancreatography (ERCP) was performed for stent placement in pancreatic or bile ducts as needed, with X-ray confirmation of stent positioning.

Locations

Country Name City State
China Beijing Friendship Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Friendship Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of complications Complications related with Endoscopic Papillectomy (EP), including pancreatitis, cholangitis, bleeding, perforation, hyperamylasemia, stenosis. The results of intraoperative endoscopic observation, postoperative symptoms and signs, blood routine examination, amylase, lipase, and imaging and endoscopic examination during follow-up were measured. through study completion, an average of 1 year
Primary Rate of complete resection The pathological margins results were used to determine whether the lesion was completely resected. 1 week after the operation
Secondary Rate of recurrence Endoscopic observation and biopsy results were used to find recurrence. Within 3 years after the operation
See also
  Status Clinical Trial Phase
Recruiting NCT04615065 - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Completed NCT03677765 - Comparisons of Complications Related to Two Approaches of Ultrasonography-guided Subclavian Venous Catheterization N/A
Recruiting NCT04249921 - Evaluation of Acupuncture Effects for Complications After Surgery of Cerebellopontine Angle Tumor in Skull Base
Completed NCT04039360 - SEMS Placement Followed by Chemotherapy and Surgery for Obstructing Left-sided Colonic Cancer
Completed NCT05238506 - Lidocaine VS Hemodynamic, Metabolic and Hormonal Response Phase 4
Recruiting NCT05429060 - A Prospective Evaluation of Hemorrhoidal Surgery Outcome in Istanbul
Enrolling by invitation NCT05725967 - Endoscopic Metabolic and Bariatric Therapies
Completed NCT05892367 - Transbrachial Access for Interventions in Patients With Peripheral Arterial Occlusive Disease N/A
Recruiting NCT05195697 - ACUTE-Acute Surgical Care- Risk Factors and Outcomes for Patients in Need of Acute Surgical Care
Completed NCT03061370 - Sarcopenia and Visceral Obesity in Esophageal and Gastric Cancer
Not yet recruiting NCT05708651 - Evaluation of Medical Device for Airway Patency During Sedation (SW01-2022) N/A
Completed NCT05903326 - Dexmedetomidine as a Sole Premedication for BMT Placement
Completed NCT04411459 - Risk Factors for Prolonged Invasive Mechanical Ventilation in COVID-19 Acute Respiratory Distress Syndrome
Recruiting NCT05886127 - Treatment of Postsphincterotomy Bleeding With a Novel Self-assembling Peptide Hemostatic Gel.
Completed NCT04432740 - A Novel Splint Technique for Distal Radius Treatment N/A